|
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 Clinical research trials and A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Phase I Randomized Dose/Formulation Comparison Study of SC-52151. A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 clinical trial. Human subjects often get the best healthcare possible for their A Phase I Randomized Dose/Formulation Comparison Study of SC-52151 condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Randomized Dose/Formulation Comparison Study of SC-52151  A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: PRIMARY: To evaluate the safety, tolerability, pharmacokinetics, and ethanol exposure of two dose regimens and formulations of SC-52151. SECONDARY: To evaluate the preliminary anti-HIV activity of these treatment regimens and the relationship between day 14 plasma concentrations of SC-52151 and immunological and virological markers and toxicity. Since viral isolates with decreased susceptibility to the protease inhibitor SC-52151 occur in vitro after multiple passages, and since prolonged post infectious effects occur in vitro, comparison of two formulations, an elixir and a self-emulsifying drug delivery system (SEDDS), is needed to determine the appropriate dose formulation for Phase II studies.
Details: Since viral isolates with decreased susceptibility to the protease inhibitor SC-52151 occur in vitro after multiple passages, and since prolonged post infectious effects occur in vitro, comparison of two formulations, an elixir and a self-emulsifying drug delivery system (SEDDS), is needed to determine the appropriate dose formulation for Phase II studies. Patients are randomized to four treatment arms to receive SC-52151 elixir or SEDDS formulation at 1 of 2 doses for 2 weeks, with follow-up for 14 days.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Pharmacokinetics Study
Minimum Age/Maximum Age: 21 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Required for patients with CD4 count <= 200 cells/mm3: - PCP prophylaxis using TMP/SMX or aerosolized pentamidine. Allowed: - Topical antifungal agents. - Up to 1000 mg/day acyclovir as maintenance therapy for herpes simplex virus. - Antibiotics for bacterial infections. - Antipyretics, analgesics, nonsteroidal anti-inflammatory agents, antiemetics, and methadone for symptomatic treatment. Patients must have: - HIV infection. - CD4 count 150 - 500 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Unable to tolerate the standard diet required for the study. - Unable to give informed consent. Concurrent Medication: Excluded: - Antiretrovirals and biologic response modifiers (including HIV vaccines). - Maintenance with ketoconazole, fluconazole, itraconazole, ganciclovir, foscarnet, pyrimethamine, sulfadiazine, clindamycin, azithromycin, isoniazid, rifampin, rifabutin, ethambutol, pyrazinamide, clofazimine, or clarithromycin. - Prophylaxis for Mycobacterial infection or fungal infections other than Candidiasis. - Allopurinol. - Omeprazole. - Astemizole. - Terfenadine. - Loratadine. - Psychotropics. - Phenylbutazone. - Barbiturates. - Benzodiazepines. - Monoamine oxidase inhibitors. - H-2 blockers. - Anticonvulsants. - Coumadin anticoagulants. - Oral contraceptives. - Antiarrhythmics. - Diltiazem. - Metronidazole. - Erythromycin. - Chloramphenicol. - Fluoroquinolones. - Disulfiram. - Erythropoietin. - G-CSF or GM-CSF. - Systemic corticosteroids. - Alcohol, including alcohol-containing medications. Patients with the following prior conditions are excluded: - Unexplained temperature >= 38.5 C for any 7 days within the 30 days prior to study entry. - Chronic diarrhea (>= three stools per day) for any 15 days within the 30 days prior to study entry. - Malignancy other than basal or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, and minimal Kaposi's sarcoma. Prior Medication: Excluded at any time: - Prior HIV protease inhibitor. Excluded within 30 days prior to study entry: - Investigational drugs. - Recombinant erythropoietin. - G-CSF or GM-CSF. - Interferon or interleukin. - Any HIV-1 vaccine. Excluded within 14 days prior to study entry: - Antiretrovirals. - Acute therapy for any opportunistic or other serious infection. - Therapy for malignancy. - Maintenance with ketoconazole, fluconazole, itraconazole, ganciclovir, foscarnet, pyrimethamine, sulfadiazine, clindamycin, azithromycin, isoniazid, rifampin, rifabutin, ethambutol, pyrazinamide, clofazimine, or clarithromycin. - Prophylaxis for Mycobacterial infection or fungal infections other than Candidiasis. Excluded within 7 days prior to study entry: - Allopurinol. - Omeprazole. - Astemizole. - Terfenadine. - Loratadine. - Psychotropics. - Phenylbutazone. - Barbiturates. - Benzodiazepines. - Monoamine oxidase inhibitors. - H-2 blockers. - Anticonvulsants. - Coumadin anticoagulants. - Oral contraceptives. - Antiarrhythmics. - Diltiazem. - Metronidazole. - Erythromycin. - Chloramphenicol. - Fluoroquinolones. - Disulfiram. Risk Behavior: Excluded: - History of substance or alcohol abuse. - Ingestion of more than 50 g alcohol daily within 6 months prior to study entry. - Recovered alcoholic.
Total Enrollment: 48
Location and Contact Information:
Overall Study Official:
FischlMA, Study Chair,
Univ of Miami School of Medicine
Miami, Florida, 331361013
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Ohio State Univ Hosp Clinic
Columbus, Ohio, 432101228
United States
Univ of California / San Diego Treatment Ctr
San Diego, California, 921036325
United States
Additional Information:
Study ID Numbers: ACTG 282;
Study Start Date:
Record last reviewed: February 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000806
Other Hiv Infections Studies:
1. A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
2. A Study of MKC-442 in Combination with Other Anti-HIV Drugs
3. A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS
4. Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
5. A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
Related Studies:
Other HIV Infections Clinical Trials
Other Ohio Clinical Trials
Other Columbus Clinical Trials
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
|
|
|
|
|
|
|
|
